טוען...
Data Interoperability of Whole Exome Sequencing (WES) Based Mutational Burden Estimates from Different Laboratories
Immune checkpoint inhibitors, which unleash a patient’s own T cells to kill tumors, are revolutionizing cancer treatment. Several independent studies suggest that higher non-synonymous mutational burden assessed by whole exome sequencing (WES) in tumors is associated with improved objective response...
שמור ב:
הוצא לאור ב: | Int J Mol Sci |
---|---|
Main Authors: | , , , , , , |
פורמט: | Artigo |
שפה: | Inglês |
יצא לאור: |
MDPI
2016
|
נושאים: | |
גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4881477/ https://ncbi.nlm.nih.gov/pubmed/27136543 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms17050651 |
תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|